Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

451

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Psoriasis
Interventions
DRUG

voclosporin

voclosporin 0.2, 0.3, or 0.4 mg/kg po BID

DRUG

Placebo

Placebo

Trial Locations (31)

T2S 3B3

Isotechnika Investigational Site, Calgary

T5J 3S9

Isotechnika Investigational Site', Edmonton

Isotechnika Investigational Site, Edmonton

V5Z 3Y1

Isotechnika Investigational Site, Vancouver

V5Z 4E8

Isotechnika Investigational Site, Vancouver

V8R 6V4

Isotechnika Investigational Site, Victoria

R3C 0N2

Isotechnika Investigational Site, Winnipeg

E1C 8X3

Isotechnika Investigational Site, Moncton

A1B 3E1

Isotechnika Investigational Site, St. John's

A1B 4F8

Isotechnika Investigational Site, St. John's

B3H 1Z4

Isotechnika Investigational Site, Halifax

L8N 1V6

Isotechnika Investigational Site, Hamilton

N5X 2P1

Isotechnika Investigational Site, London

N6A 3H7

Isotechnika Investigational Site, London

L4K 5V2

Isotechnika Investigational Site, Maple

L3P 1A8

Isotechnika Investigational Site, Markham

L3Y 6P5

Isotechnika Investigational Site, Newmarket

L4M 6L2

Isotechnika Investigational Site, North Bay

P1B 3Z7

Isotechnika Investigational Site, North Bay

L6K 1E1

Isotechnika Investigational Site, Oakville

L1H 1B9

Isotechnika Investigational Site, Oshawa

M5V 2T3

Isotechnika Investigational Site, Toronto

N2J 1C4

Isotechnika Investigational Site, Waterloo

N8W 1E6

Isotechnika Investigational Site, Windsor

N8W 5L7

Isotechnika Investigational Site, Windsor

H7G 2C0

Isotechnika Investigational Site, Laval

H2K 4L5

Isotechnika Investigational Site, Montreal

H3G 1C6

Isotechnika Investigational Site, Montreal

H9R 4S3

Isotechnika Investigational Site, Pointe-Claire

J1J 2B8

Isotechnika Investigational Site, Sherbrooke

G1V 4X7

Isotechnika Investigational Site, Ste. Foy

Sponsors
All Listed Sponsors
lead

Aurinia Pharmaceuticals Inc.

INDUSTRY